patent.fyi
Applications  /  US 2026/0355136
United States Patent Application Publication

US 2026/0355136 A1

Published
Nov 12, 2026
Filed
Jul 4, 2024
Earliest date on the face
Jul 5, 2023
Classification
A61K 31/192
First published here
Nov 19, 2026

Generated automatically. Not reviewed by a person. Not legal advice or an opinion.

Section 1 · machine-generated

What if?

Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.

1.1Sulfur linkage to methyl

What ifWhat if R1 carries a methylthio group with sulfur between the scaffold and the methyl carbon?
Claim language“substituted or unsubstituted C1-C6 alkoxy”

The scaffold bonds to sulfur, and sulfur bonds to the methyl carbon. The thioether retains a one-carbon terminal group and places a larger, more polarizable atom at the attachment point.

1.2Four fluorines on phenyl

What ifWhat if a phenyl group at R1 carries four fluorine substituents?
Claim language“1, 2 or 3 substituents”

Fluorine occupies positions 2, 3, 5 and 6 on the phenyl ring, counting the scaffold attachment as position 1. The two fluorines next to the attachment flank the scaffold–aryl bond, and all four withdraw electron density through the ring's sigma bonds.

1.4Fused six-membered rings

What ifWhat if R1 and R2 form a fused pair of six-membered carbon rings with their attachment carbons as the ring junction?
Claim language“C3-C8 bridged cycloalkyl”

The rings share the bond between the two attachment carbons. A trans junction places the junction hydrogens on opposite faces and locks both rings in chair conformations.

1.5Hydrogen at both positions

What ifWhat if both R1 and R2 are hydrogen?
Claim language“R1 and R2 are not simultaneously hydrogen”

Each designated substituent bond terminates in hydrogen. This leaves a smaller steric footprint at both attachment sites while preserving the scaffold's carbon connectivity.

1.6Phenyl on a methylene

What ifWhat if R3 is benzyl, with a phenyl ring attached through a methylene group?
Claim language“halogenated C3-C8 cycloalkyl”

The methylene carbon connects the phenyl ring to the R3 attachment point. The phenyl ring supplies a hydrophobic surface, and rotation about the methylene–phenyl bond lets that surface change orientation.

Section 2 · machine-generated

Variations

Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.

Other field of use

Veterinary pulmonary artery tissue assay

Rings of porcine pulmonary artery mount between a fixed hook and a force transducer in an oxygenated physiological buffer. The bath receives a contractile stimulus, followed by increasing concentrations of a formula (I) compound. The transducer records tension after each addition, and relaxation is expressed as a percentage of the tension generated by the contractile stimulus.

Component substitution

Hydroxyethylammonium counterion for the carboxylate

A protonated ethanolamine counterion replaces the inorganic metal ion at R5. One molar equivalent of ethanolamine is added to the free acid in aqueous ethanol to form the carboxylate salt. The solvent is removed under reduced pressure, and proton nuclear magnetic resonance measures the ratio of ethanolamine to the prostacyclin derivative.

Oxetane ring at the substituent positions

A four-membered oxetane ring replaces the independent R1 and R2 substituents. The two scaffold carbons at those positions form one edge of the ring, and a methylene group and an ether oxygen complete the ring. An oxetane-containing intermediate carries both scaffold attachment points into the coupling step, and two-dimensional nuclear magnetic resonance verifies ring connectivity.

Parameter or scale variation

Temperature series for solution stability

A solution of a formula (I) salt is divided into sealed 1 mL aliquots and held at 5, 25, and 40 °C. Aliquots from each temperature group are analyzed at 0, 24, and 72 hours using liquid chromatography with mass spectrometric detection. Calibration against the parent compound gives the percentage remaining at each time point, and additional chromatographic peaks track the appearance of degradation products.

Combination with existing systems

Nebulizer coupled to a breathing simulator

An aqueous solution of a formula (I) salt fills the reservoir of a vibrating mesh nebulizer connected to a breathing simulator. The simulator draws aerosol through a collection filter during inspiration and routes exhaled flow through a separate outlet. Liquid chromatography measures the compound recovered from the inspiratory filter, and the recovered mass is divided by the number of simulated breaths.

Automated or data-driven variant

Automated analysis of receptor concentration responses

A liquid handling robot dispenses serial dilutions of formula (I) compounds into wells containing cells that express the prostacyclin receptor. The plate includes vehicle controls and receptor-negative cells, and a plate reader measures intracellular cyclic adenosine monophosphate with a homogeneous fluorescence assay. Software subtracts the vehicle signal, fits a four-parameter logistic curve to each concentration series, and reports the half-maximal effective concentration and fitted maximum response.

Specific version of a part

Terminal ethynyl at R1

R1 is ethynyl and R2 is hydrogen. The scaffold bonds directly to one carbon of the triple bond, and the other carbon bears a terminal hydrogen.

Para methoxy on phenyl

R is methoxy on a phenyl ring, with the methoxy group at position 4 relative to the ring's attachment to the rest of the molecule. The ring bonds to the methoxy oxygen, which in turn bonds to a methyl carbon.

Acetyl paired with hydrogen

R3 is acetyl and R4 is hydrogen. The acetyl group connects at the R3 position through its carbonyl carbon, which also bonds to a methyl group.

Sodium as the counterion

R5 is sodium in the carboxylate salt. One sodium ion balances the negative charge of each carboxylate group, and both ions become hydrated when the salt dissolves in water.

Section 3 · quoted from USPTO records

Other work

Passages reproduced word for word from two earlier-published U.S. patent documents, placed beside the language of claim 1. No characterization is offered. Each passage is marked A or B for the document it comes from; ¶ numbers are the paragraph numbers in the USPTO’s published full text of that document.

Document AUS 2009/0137573 A1
Published
May 28, 2009
Filed
Dec 9, 2008
Class
A61K 31/541
Document BUS 7,951,815 B2
Published
May 31, 2011
Filed
Sep 22, 2006
Class
A61K 31/438
Claim 1
Document A
Document B
1.1hydrogen, deuterium, halogen, hydroxy, amino, substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted C2-C6 alkenyl, substituted or unsubstituted C2-C6 alkynyl, substituted or unsubstituted C1-C6 alkoxy, substituted or unsubstituted C3-C8 cycloalkyl, substituted or unsubstituted 4- to 8-membered heterocycloalkyl containing 1, 2 or 3 heteroatoms selected from N, O or S, substituted or unsubstituted C6-C10 aryl, substituted or unsubstituted 5- to 10-membered heteroaryl containing 1, 2 or 3 heteroatoms selected from N, O or S
in which R1 denotes unsubstituted or at least monosubstituted alkyl, alkenyl or alkynyl; unsubstituted or at least monosubstituted heteroalkyl, heteroalkenyl or heteroalkynyl; unsubstituted or at least monosubstituted cycloalkyl or cycloalkenyl; unsubstituted or at least monosubstituted heterocycloalkyl or heterocycloalkenyl; unsubstituted or at least monosubstituted-(alkylene)-cycloalkyl, -(alkenylene)-cycloalkyl, -(alkynylene)-cycloalkyl, -(alkylene)-cycloalkenyl, -(alkenyl
A · US 2009/0137573 A1 · ¶
R1 stands for a hydrogen radical, a C1-6-alkyl radical, a C1-6 alkoxy radical, a C2-6 hydroxyalkyl radical, a C2-6 alkenyl radical, a C2-6 alkynyl radical, a phenyl radical or for a C1-6-alkyl radical that is monosubstituted, disubstituted, or trisubstituted by a phenyl radical, R2 stands for a hydrogen radical, a C1-6-alkyl radical, a C1-6 alkoxy radical, a C2-6 hydroxyalkyl radical, a C2-6 alkenyl radical, a C2-6 alkynyl radical, a phenyl radical, a C1-6-alkyl radical monos
B · US 7,951,815 B2 · ¶
1.2‘substituted’ refers to independent substitution by 1, 2 or 3 substituents selected from the group consisting of deuterium, halogen, hydroxyl, amino, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, C3-C8 cycloalkyl, 4- to 8-membered heterocycloalkyl containing 1, 2 or 3 heteroatoms selected from N, O or S, R-substituted or unsubstituted C6-C10 aryl, R-substituted or unsubstituted 5- to 10-membered heteroaryl containing 1, 2 or 3 heteroatoms selected from N, O or S
If one or more of the substituents denote a cycloalkyl residue, heterocycloalkyl residue, cycloalkenyl residue or heterocycloalkenyl residue or comprise such a residue, which is mono- or polysubstituted, this may preferably be optionally substituted with 1, 2, 3, 4 or 5, particularly preferably with optionally 1, 2 or 3, substituents independently selected from the group consisting of F, Cl, Br, I, —CN, —CF3, —OH, —NH2, —O—CF3, —SH, —O—C1-5-alkyl, —O-phenyl, —O—CH2-phenyl, —(
A · US 2009/0137573 A1 · ¶ 48
(CH2)-benzo[b]furanyl; —O-phenyl; —O-benzyl; phenyl; benzyl, naphthyl and —(CH2)-naphthyl, and each of the cyclic moieties of the —O-phenyl, —O-benzyl, phenyl, —(CH2)-benzo[b]furanyl, benzyl, naphthyl and —(CH2)—naphthyl groups optionally may be substituted by from 1 to 5 substituents independently selected from the group consisting of F, Cl, Br, —OH, —CF3, —SF5, —CN, —NO2, —OC1-5 alkyl, —C1-5 alkyl, —OCF3, —SCF3, phenyl, and —O-benzyl; wherein monosubstituted and polysubstit
B · US 7,951,815 B2 · claim 1
1.3R is selected from the group consisting of halogen, hydroxyl, C1-C6 alkyl, C1-C6 alkoxy
(CH2)-benzo[b]furanyl; —O-phenyl; —O-benzyl; phenyl; benzyl, naphthyl and —(CH2)-naphthyl, and each of the cyclic moieties of the —O-phenyl, —O-benzyl, phenyl, —(CH2)-benzo[b]furanyl, benzyl, naphthyl and —(CH2)—naphthyl groups optionally may be substituted by from 1 to 5 substituents independently selected from the group consisting of F, Cl, Br, —OH, —CF3, —SF5, —CN, —NO2, —OC1-5 alkyl, —C1-5 alkyl, —OCF3, —SCF3, phenyl, and —O-benzyl; wherein monosubstituted and polysubstit
B · US 7,951,815 B2 · claim 1
1.4or R1, R2 together with the C atoms to which they are attached form C3-C8 monocyclic cycloalkyl, C3-C8 bridged cycloalkyl, C7-C10 spirocycloalkyl, or 4- to 8-membered heterocycloalkyl containing 1, 2 or 3 heteroatoms selected from N, O or S
R2 denotes H; unsubstituted or at least monosubstituted alkyl, alkenyl or alkynyl; unsubstituted or at least monosubstituted heteroalkyl, heteroalkenyl or heteroalkynyl; unsubstituted or at least monosubstituted aryl; or unsubstituted or at least monosubstituted-(alkylene)-aryl, -(alkenylene)-aryl, -(alkynylene)-aryl; or R1 and R2 together with the nitrogen atom to which they are bound denote heterocycloalkyl or heterocycloalkenyl, which is unsubstituted or substituted with a
A · US 2009/0137573 A1 · ¶
1.5R1 and R2 are not simultaneously hydrogen
in which R1 denotes unsubstituted or at least monosubstituted alkyl, alkenyl or alkynyl; unsubstituted or at least monosubstituted heteroalkyl, heteroalkenyl or heteroalkynyl; unsubstituted or at least monosubstituted cycloalkyl or cycloalkenyl; unsubstituted or at least monosubstituted heterocycloalkyl or heterocycloalkenyl; unsubstituted or at least monosubstituted-(alkylene)-cycloalkyl, -(alkenylene)-cycloalkyl, -(alkynylene)-cycloalkyl, -(alkylene)-cycloalkenyl, -(alkenyl
A · US 2009/0137573 A1 · ¶
1.6R3 and R4 are independently selected from the group consisting of hydrogen, —(C═O)—C1-C6 alkyl, C1-C6 alkyl, halogenated C1-C6 alkyl, C3-C8 cycloalkyl, and halogenated C3-C8 cycloalkyl
R3 represents hydrogen; a linear or branched unsubstituted or at least monosubstituted alkyl group which may comprise at least one heteroatom as a link; or a linear or branched unsubstituted or at least monosubstituted alkenyl group which may comprise at least one heteroatom as a link; a linear or branched unsubstituted or at least monosubstituted alkynyl group which may comprise at least one heteroatom as a link; an unsubstituted or at least monosubstituted aryl group or het
B · US 7,951,815 B2 · claim 1
1.7R5 is selected from the group consisting of hydrogen, C1-C6 alkyl, halogenated C1-C6 alkyl, C3-C8 cycloalkyl, halogenated C3-C8 cycloalkyl, inorganic metal ion, and ammonium ion.
R5 and R6 each independently are a linear or branched alkyl group; a linear or branched alkenyl group; or a linear or branched alkynyl group;
B · US 7,951,815 B2 · claim 1

An empty cell means only that no passage was reproduced there.

Statements in these documents
There is a worldwide need for effective pain treatments.
A · US 2009/0137573 A1 · ¶ 3
A particular object of the invention was to provide new compounds suitable for use in the treatment and/or inhibition of acute pain, chronic pain and/or neuropathic pain.
A · US 2009/0137573 A1 · ¶ 7
There is thus a great need for suitable active pharmacological substances which inhibit reuptake of 5-hydroxytryptophane (serotonin) and are therefore particularly suitable for the therapy of obesity.
B · US 7,951,815 B2 · ¶ 3
It is thus an object of the present invention to provide compounds which are particularly suitable for use as pharmaceutically active substances in medicinal drugs, preferably in medicinal drugs for the inhibition and/or treatment of obesity.
B · US 7,951,815 B2 · ¶ 4
Cite aspatent.fyi, US 2026/0355136 A1, claim 1, first published 2026-11-19T08:28:42-05:00, https://patent.fyi/US20260355136/, SHA-256 5f4c3a9a4b8a9c021579d84dd9c445aa41da3756c1ceb6808b8e6fced886a5b2
First published
Permanent addresshttps://patent.fyi/US20260355136/
Content fingerprint (SHA-256)5f4c3a9a4b8a9c021579d84dd9c445aa41da3756c1ceb6808b8e6fced886a5b2
Methodv2026-11-18.2 · automated, not reviewed by a person
Correctionscorrections@patent.fyi